On November 4, 2026, Veneno Technologies gave a short pitch and presented a poster at “OIST-Lifetime Startup Elevate 2026,” held at the Okinawa Institute of Science and Technology (OIST).
CEO Takatoshi Kuno introduced the company’s drug discovery approach using venom-derived disulfide-rich peptides (DRPs). The presentation highlighted how Veneno combines AI with data from its own lab to identify peptide candidates that act on membrane proteins that have been difficult to target with existing approaches.
Related link:
OIST-Lifetime Startup Elevate 2026 Official Website
